Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,484,801

« Back to Dashboard
Patent 5,484,801 protects KALETRA and NORVIR and is included in two NDAs. There have been zero Paragraph IV challenges on Kaletra and Norvir There are eight tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in fourteen countries.

Summary for Patent: 5,484,801

Title: Pharmaceutical composition for inhibiting HIV protease
Abstract:A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.
Inventor(s): Al-Razzak; Laman A. (Libertyville, IL), Marsh; Kennan C. (Lake Forest, IL), Manning; Lourdes P. (Grayslake, IL), Kaul; Dilip (Waukegan, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/440,277
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
lopinavir; ritonavir
SOLUTION;ORAL021251-001Sep 15, 2000RXYes5,484,801*PED<disabled>
SOLUTION;ORAL020659-001Mar 1, 1996RXYes5,484,801*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,484,801

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
Israel111991Jul 26, 2000
Canada2178632Apr 11, 2006
Austria210441Dec 15, 2001
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn